Flaviviridae infectious disease

This early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…

This Phase 2 study tests a new yellow fever vaccine (vYF) against the current licensed vaccine (Stamaril) in 690 healthy adults aged 18-60 in Europe and Asia. Participants receive one shot, and researchers measure immune response and safety over 5 years. The goal is to see if the…

This phase 3 trial is testing whether a new formulation of Takeda's dengue vaccine (TDV) works as well as the current approved version. About 496 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. The main goal is to compare immune resp…

This study aimed to test a drug called IC14 in adults with early dengue fever to see if it is safe and could help reduce symptoms and viral levels. It was designed for people in areas where dengue is common, but the trial was withdrawn before any participants were enrolled. No re…

This study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study tests whether anakinra, an anti-inflammatory drug, can help people with severe dengue who have dangerously high inflammation. About 160 adults and children will receive either anakinra or a placebo for four days. The goal is to see if anakinra reduces organ failure and…

This expanded access program offers SkinTE, a treatment made from a small piece of the patient's own healthy skin, to people with Wagner 1 diabetic foot ulcers. The goal is to see if applying these skin cells directly to the wound can help it heal. The program also collects safet…

This study tests whether papaya leaf extract syrup can raise low platelet counts in children aged 2–12 with dengue fever. One hundred children will receive either standard care alone or standard care plus the extract for three days. Researchers will compare platelet changes and w…

This study compares a new device, cureVision cV, to an existing one (MolecuLight i:X) to see if it can accurately detect moderate to high levels of bacteria in wounds. About 100 adults with various wound types (like diabetic foot ulcers or surgical wounds) will be enrolled. The g…

This study evaluates a new blood test called Xpert Tropical Fever that can quickly detect several tropical diseases like malaria, dengue, and Zika from a small blood sample. Researchers will enroll 2,500 people with fever symptoms to see how accurate the test is compared to stand…

This small study is testing Corplex P, a device made from donated human umbilical cord tissue, to see if it helps heal wounds that won't close on their own, like diabetic foot ulcers. Ten people will receive the device as part of their standard wound care. Researchers will track …

This study explores how low-level laser therapy (LLLT) affects skin stiffness and thickness. Researchers will use a special imaging system to track tiny skin movements in 20 healthy adults. The goal is to find the best laser settings for future wound healing treatments.

This study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and e…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study tracks side effects and severe dengue cases in 2,000 people who already got the QDENGA dengue vaccine in Malaysia. No new vaccine is given—researchers simply collect health data from participants. The goal is to understand real-world safety and whether vaccinated peopl…

This study aims to improve how we predict and prevent dengue outbreaks by looking at how people move around the city. Researchers in Cuba will collect information from 810 residents about their daily travel, along with mosquito and weather data. The goal is to build better comput…

This study reviews the records of up to 800,000 people who received the TAK-003 (Qdenga) dengue vaccine at VNVC centers in Vietnam between September 2024 and September 2025. Researchers will look at age, sex, location, and vaccination history to see who got the vaccine and how. N…

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study, run by Fudan University and local health authorities, uses computer models to predict the best way to use dengue vaccines in Yunnan, China. Researchers will collect blood samples from 220 residents to measure antibody levels and simulate different vaccination scenario…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This study looks at how the Takeda dengue vaccine (TAK-003) activates T-cells, a key part of the immune system. Researchers will vaccinate 30 healthy adults and analyze their T-cell and antibody responses over 26 weeks. The goal is to find reliable markers of protection, which co…